A retrospective longitudinal cohort study of 3,637 adults with moderate-to-severe depression reports that higher subjective psychedelic intensity at 2 weeks of sublingual ketamine treatment was associated with greater reductions in depression severity at 4 weeks.
Helus Pharma, formerly Cybin, announced a positive topline readout from its first phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). The trial is part of the company's PARADIGM phase 3 program, which tests HLP003 as an adjunctive treatment in adults who have had an inadequate response. The announcement gives no effect size, adverse event data or participant numbers.
Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.
Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.
DoubleBlind reports that the nonprofit Usona Institute reportedly submitted a New Drug Application to the FDA on November 2, 2026 for its synthetic psilocybin candidate for major depressive disorder (MDD), a filing first reported by Psychedelic Alpha that Usona declined to comment on.
Compass Pathways said in its Q3 2026 results that its new drug application for COMP360 psilocybin for treatment-resistant depression (TRD) is nearing completion and will be filed in the next two weeks. The release describes the final NDA submission as nearing completion. The company declined to comment on Usona.
Usona Institute has completed its submission of a new drug application to the US Food and Drug Administration for its psilocybin candidate for major depressive disorder.
NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.
Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.
30 OctFri
Friday
Europe PMC: new psychedelic research papersAI score5555
A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.
The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.
Compass Pathways chief executive Kabir Nath said the company will "go slow before we go fast" as it prepares to complete a rolling FDA submission this quarter for COMP360.
Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.
The U.S. Department of Veterans Affairs launched PIVOT on August 5, a five-site trial of Compass Pathways' COMP360 psilocybin in veterans with treatment-resistant depression.
Definium Therapeutics said on Monday that its LSD therapy DT120 significantly helped patients with major depression in its first Phase 3 trial. Six weeks after a single dose.
Why it matters: The topline gives the first Phase 3 readout for an LSD-based depression treatment, so the size of the placebo gap and the waning at 12 weeks are the numbers that will shape the next regulatory step.